Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist that acts as a long-acting analog of the natural hormone GLP-1, used to treat type 2 diabetes and obesity. It works by enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. It is commonly known by brand names like Ozempic and Wegovy. 

Key Features & Mechanism

• Mechanism: Semaglutide is a modified peptide structure with a 31-amino acid sequence, featuring a fatty acid chain that allows it to bind to albumin, significantly extending its half-life to roughly one week.
• Appetite Control: It mimics GLP-1 to enhance satiety and decrease hunger, leading to reduced food intake and significant weight loss, often reported around 15% in clinical trials.
• Glucose Management: It improves glycemic control by stimulating insulin release when blood sugar is high.  Veltrix Peptides.

Clinical Uses and Approval

• Type 2 Diabetes: Used for blood sugar regulation.
• Weight Loss: Approved for chronic weight management in adults with obesity or weight-related conditions.
• Cardiovascular Health: Known to reduce the risk of cardiovascular events, such as stroke or heart attack, in patients with diabetes.

Administration and Safety

• Dosage Form: Typically administered as a weekly subcutaneous injection, though an oral option exists.
• Side Effects: The most common adverse effects are gastrointestinal, including nausea, vomiting, diarrhea, abdominal pain, and constipation.
• Storage: The peptide is typically stored in the refrigerator. 

Side effects

Possible adverse effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion/heartburn, dizziness, abdominal distension, belching, hypoglycemia (low blood glucose) in people with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease (GERD).^[15] It has in the past been suspected to cause pancreatitis, and can cause gastroparesis and bowel obstruction.^[42] Among people who were prescribed a glucagon-like peptide-1 (GLP-1) medication, 0.1% were diagnosed with gastroparesis at least six months later, which equates to a 52% increased risk of being diagnosed with gastroparesis while on a GLP-1 medication.^[43] A 2019 meta-analysis did not indicate a significantly elevated risk of acute pancreatitis.^[44]

The US prescription label for semaglutide contains a boxed warning for thyroid C-cell tumors in rodents.^{[13][14][15][45]} It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.^{[13][14][15][45][46]}

In January 2026, the US Food and Drug Administration requested removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.

Important Notes
Semaglutide should only be used under medical supervision. It is not approved for use in combination with other GLP-1 receptor agonists, and potential side effects may include rare risks like pancreatitis or thyroid C-cell tumors.